Sagimet Biosciences Reports Q4 and Full Year 2025 Results – Key Clinical and Corporate Advances

Sagimet Biosciences Inc. (Nasdaq: SGMT) has released its financial results for the fourth quarter and full year ended December 31, 2025, accompanied by significant corporate updates and milestones that could be highly relevant for investors and shareholders.

Key Highlights

• Completion of Phase 1 PK Clinical Trial: Sagimet completed an open-label Phase 1 clinical trial evaluating the pharmacokinetics (PK), drug-drug interactions (DDI), and safety/tolerability of its oral FASN inhibitor, denifanstat, in combination with the THR-β agonist resmetirom. The combination was generally well-tolerated, with no safety signals, serious adverse events, or treatment discontinuations. This trial lays the foundation for a planned Phase 2 proof-of-concept trial targeting F4 MASH patients, a population currently without approved treatments. The Phase 2 trial is expected to initiate in the second half of 2026, subject to regulatory consultation.
• Exclusive Global License Agreement with TAPI (Teva subsidiary): Sagimet has secured a global, exclusive license to innovative forms of resmetirom API from TAPI, enabling technical evaluation, manufacture, and potential development of a fixed-dose combination (FDC) of denifanstat and resmetirom. Patent applications covering both the FDC and innovative API forms are pending, which may provide a competitive advantage and intellectual property protection.
• Progress in Acne Program: Ascletis, Sagimet’s license partner in China, reported positive topline results from an open-label Phase 3 trial evaluating the long-term safety of denifanstat (ASC40) in moderate to severe acne patients. The trial enrolled 240 subjects for up to 40 weeks, with total exposure reaching 52 weeks for some participants. Denifanstat was generally well-tolerated and showed improvements across all efficacy endpoints, supporting Ascletis’ NDA submission, which was accepted by China’s National Medical Products Administration (NMPA).
• First-in-Human Trial of TVB-3567: Sagimet initiated a randomized, double-blind, placebo-controlled Phase 1 trial of TVB-3567, another FASN inhibitor intended for acne. Results from this study will inform the planned Phase 2 trial in moderate to severe acne patients in 2026.

Clinical Data and Publications

• Fibrosis Improvement in MASH: Secondary analysis from the denifanstat Phase 2b FASCINATE-2 clinical trial demonstrated significant ≥2-stage improvement in fibrosis among F3 MASH patients, alongside improved liver fibrosis and noninvasive biomarkers in a subpopulation of qFibrosis stage 4 MASH patients (identified by AI-based digital pathology).
• Predictive Analysis: Spatial computational histology based on baseline fibrosis features was used to predict response to denifanstat, suggesting an advanced approach for patient stratification and outcome prediction.

Financial Performance

• Cash Position: Sagimet ended 2025 with \$113.1 million in cash, cash equivalents, and marketable securities.
• R&D Expenses: Research and development expenses were \$6.7 million for Q4 and \$39.1 million for the full year, compared to \$14.2 million and \$38.4 million respectively in 2024.
• General & Administrative Expenses: G&A expenses were \$4.0 million for Q4 and \$17.8 million for the year, up slightly from \$4.0 million and \$16.0 million in 2024.
• Net Loss: Net loss was \$9.6 million for Q4 and \$51.0 million for the year, compared to \$16.2 million and \$45.6 million in 2024. The increase in net loss reflects sustained investment in clinical development and operational expansion.
• Balance Sheet: Total assets stood at \$116.5 million with stockholders’ equity at \$111.4 million at year-end, and current liabilities at \$5.1 million.

Anticipated Milestones in 2026

• Initiation of Phase 2 proof-of-concept trial for the denifanstat/resmetirom combination in F4 MASH patients (H2 2026).
• Initiation of Phase 2 trial for TVB-3567 in moderate to severe acne following completion of the Phase 1 trial and regulatory consultation.

Potentially Price-Sensitive Developments

• First-in-class F4 MASH Treatment: Progress toward a Phase 2 trial for F4 MASH, a patient population with no approved therapies, could be a pivotal value driver.
• Chinese Market Access: Acceptance of Ascletis’ NDA for denifanstat in China positions Sagimet for potential revenue generation and market expansion in a large, underserved population.
• Intellectual Property Strengthening: Exclusive licensing and pending patents for innovative resmetirom API forms and combination products may create barriers to entry and boost long-term shareholder value.
• Clinical Data Validation: Positive safety and efficacy signals from long-term acne trials and fibrosis improvement in MASH may enhance investor confidence in Sagimet’s pipeline and commercial prospects.

Background on Therapeutic Areas

MASH (Metabolic Dysfunction-Associated Steatohepatitis): A progressive liver disease affecting over 265 million globally, with advanced fibrosis (F3/F4) patients at highest risk for adverse outcomes. There are currently few approved treatments for non-cirrhotic MASH and none for cirrhosis (F4).

Acne: Over 50 million in the U.S. suffer from acne, a chronic condition often requiring oral therapies due to low adherence to topicals. FASN inhibition is a promising approach due to its role in sebum production and inflammation.

Summary

Sagimet Biosciences’ recent clinical and corporate milestones, including progress toward first-in-class therapies for F4 MASH and moderate to severe acne, exclusive licensing agreements, and positive long-term safety data, are highly relevant for shareholders. The pipeline advances, intellectual property strengthening, and market access in China could drive significant value and are likely to be closely watched by investors.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, including those described in Sagimet Biosciences’ SEC filings. Investors should conduct their own research and consult financial advisors before making investment decisions.

View Sagimet Biosciences Inc. Historical chart here